An update from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:RMD) ) is now available.
ResMed Inc. reported significant growth in its second quarter of fiscal year 2025, with a 10% increase in revenue to $1.3 billion and a 52% rise in income from operations. The company’s focus on sleep and breathing health products, alongside digital health solutions, has led to improved margins and a substantial operating cash flow of $309 million. The results underscore ResMed’s strategic positioning to capitalize on emerging opportunities in the digital health market, particularly with the integration of consumer wearables and advancements in GLP-1 therapies.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, focusing on sleep health and breathing health products and digital health solutions. The company is known for its connected digital health ecosystem and aims to leverage consumer wearables and GLP-1 therapies to enhance patient care at home.
YTD Price Performance: 9.17%
Average Trading Volume: 873,819
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$58.81B
See more insights into RMD stock on TipRanks’ Stock Analysis page.
